摘要
目的:探讨大剂量氨溴索联合左氧氟沙星治疗老年慢性阻塞性肺疾病(COPD)伴重症肺炎的疗效。方法:选取2017年10月-2020年9月在东莞市横沥医院接受治疗的56例老年COPD伴重症肺炎患者作为研究对象,使用抽签法将其分为对照组与观察组,各28例,对照组采用常规剂量的氨溴索联合左氧氟沙星进行治疗,观察组采用大剂量氨溴索联合左氧氟沙星进行治疗。比较两组患者治疗前后C反应蛋白(CRP)、降钙素原(PCT)、最大呼气第一秒呼气量容积(FEV1)及用力肺活量(FVC)水平。结果:两组患者治疗前CRP及PCT水平比较,差异无统计学意义(P>0.05);治疗后,两组患者CRP及PCT水平均较治疗前降低,差异有统计学意义(P<0.05)。观察组治疗后CRP及PCT水平均低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前FEV1及FVC值比较,差异无统计学意义(P>0.05);治疗后,两组患者FEV1及FVC值均较治疗前升高,差异有统计学意义(P<0.05)。观察组治疗后FEV1及FVC值均高于对照组,差异有统计学意义(P<0.05)。结论:大剂量氨溴索联合左氧氟沙星治疗老年COPD伴重症肺炎患者,有助于降低CRP、PCT水平,减轻炎症反应,同时能有效改善患者的肺功能。
Objective:To investigate the efficacy of high-dose ambroxol combined with levofloxacin in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD)and severe pneumonia.Methods:A total of 56 elderly patients with COPD and severe pneumonia who were treated in Dongguan Hengli Hospital from October 2017 to September 2020 were selected as the study subjects,and they were divided into control group and observation group by lottery method,with 28 cases in each group.The control group was treated with conventional-dose ambroxol combined with levofloxacin,and the observation group was treated with high-dose ambroxol combined with levofloxacin.The levels of C-reactive protein(CRP),procalcitonin(PCT),forced expiratory volume in one second(FEV1)and forced vital capacity(FVC)were compared between the two groups before and after treatment.Results:There was no significant difference in the levels of CRP and PCT between the two groups before treatment(P>0.05);after treatment,the levels of CRP and PCT in the two groups were lower than those before treatment,and the difference was statistically significant(P<0.05).After treatment,the levels of CRP and PCT in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in FEV1and FVC values between the two groups before treatment(P>0.05);after treatment,the FEV1and FVC values in the two groups were higher than those before treatment,and the difference was statistically significant(P<0.05).After treatment,the FEV1and FVC values of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Conclusion:High-dose ambroxol combined with levofloxacin in the treatment of elderly patients with COPD and severe pneumonia can help reduce the levels of CRP and PCT,reduce the inflammatory response,and can effectively improve the pulmonary function of the patients.
作者
陈兰芳
周志森
张锦棠
Chen Lan-fang;Zhou Zhi-sen;Zhang Jin-tang(Department of Critical Care Medicine,Hengli Hospital,Dongguan 523460,Guangdong Province,China)
出处
《中国社区医师》
2022年第20期45-47,共3页
Chinese Community Doctors
关键词
大剂量氨溴索
左氧氟沙星
老年慢性阻塞性肺疾病
重症肺炎
High-dose ambroxol
Levofloxacin
Elderly chronic obstructive pulmonary disease
Severe pneumonia
